Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5182)	12/20/2001 12:52:53 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

And here's a new twist - a marketing venture for an existing product. Don't know if this is an earnings ploy (keep the additional marketing expense off the income statement) or what. Thursday December 20, 10:45 am Eastern Time Press Release SOURCE: Cephalon, Inc. Cephalon, Inc. Announces New Marketing and Sales Venture WEST CHESTER, Pa., Dec. 20 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH - news) today announced formation of a joint venture company to invest in the expansion of commercialization activities that are intended to increase sales of two of Cephalon's pharmaceutical products marketed in the United States. Investors in the joint venture will contribute approximately $50 million in cash to support the additional commercial activities. The joint venture will invest the money over a two-year period in marketing and new commercial programs for two of Cephalon's high-growth U.S. products -- PROVIGIL® (modafinil) Tablets [C-IV] and GABITRIL® (tiagabine hydrochloride). ``This transaction allows Cephalon to increase its investment in commercial products and thereby increase their value,'' said J. Kevin Buchi, senior vice president and chief financial officer of Cephalon. Peter